Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Medical Genetics · DYRK1A Syndrome

The Genetics of DYRK1A Syndrome and Diagnostic Testing

At a Glance

DYRK1A syndrome usually results from a new, harmful change or deletion in one copy of the DYRK1A gene. Sequencing, chromosomal microarray, and sometimes DNA-methylation fingerprint testing can confirm the diagnosis and clarify the chance it could occur again in a family.

Understanding the genetic cause of DYRK1A syndrome can help families make sense of their child’s symptoms and plan for the future. This condition is caused by changes in the DYRK1A gene, located on chromosome 21 [1][2].

The Biological Cause: Haploinsufficiency

Your body typically has two copies of the DYRK1A gene—one from each parent. These genes provide the instructions for making a protein that is essential for brain development and growth [3].

DYRK1A syndrome occurs because of haploinsufficiency. This is a medical term meaning that one copy of the gene is either missing or not working correctly, leaving the body with only half the amount of protein it needs [1][4]. This “dosage” problem prevents the brain from growing and communicating as it should, leading to the symptoms seen in the syndrome [3][5].

Why Most Cases Are “De Novo”

In the vast majority of families, DYRK1A syndrome is de novo. This is a Latin phrase meaning “from the beginning” or “new” [2][6].

  • What it means: The genetic change happened randomly in the sperm or egg, or very early in the baby’s development. It was not present in the parents’ blood and was not caused by anything the parents did or did not do [2].
  • Recurrence Risk: If sensitive blood testing confirms the variant is de novo and neither parent carries it, the chance of having another child with the same condition is generally quoted as less than 1% [6][7].
  • A Note on Mosaicism: While rare, there is a tiny possibility that a parent carries the mutation only in their reproductive cells (germline mosaicism), meaning the risk is never exactly zero. Because standard blood tests might not catch this, doctors often recommend targeted testing in future pregnancies. If a parent does carry the variant, recurrence risk is 50% [8][9]. A genetic counselor can discuss targeted prenatal diagnosis or preimplantation genetic testing.

Testing Methods to Confirm the Diagnosis

Because DYRK1A syndrome shares features with many other conditions, specialized genetic testing is required for a definitive answer. Different tests have different strengths:

  • Whole Exome or Genome Sequencing: This scans the “coding” parts of genes to find small spelling errors (point mutations) in the DYRK1A gene. While highly sensitive, it can miss large structural changes or deep intronic variants [9][10].
  • Chromosomal Microarray (CMA): This test looks for larger chunks of missing genetic material. It can identify if the entire DYRK1A gene—or a large piece of it—is deleted [10][11].
  • Episignature Testing: If a test finds a change in the DYRK1A gene but the doctors aren’t sure if it’s the cause of the symptoms (a “Variant of Uncertain Significance” or VUS), they can sometimes use a newer test called a DNA-methylation episignature. This test looks for a specific “chemical fingerprint” that DYRK1A syndrome leaves on the DNA [9][12]. However, it is not universally available, and a Variant of Uncertain Significance should not by itself be used to change treatment or make reproductive decisions.

Differentiating DYRK1A from Similar Conditions

Because phenotypic overlap makes visual diagnosis unreliable, molecular testing is required to distinguish DYRK1A syndrome from Angelman-like disorders. These conditions can look remarkably similar but have completely different genetic causes.

Feature DYRK1A Syndrome Angelman Syndrome HNRNPH2 / DOCK4
Genetic Cause DYRK1A gene (Chr 21) [2] UBE3A gene (maternal imprinting loss, Chr 15) [13] HNRNPH2 or DOCK4 genes [14][15]
Head Size Small at birth or soon after [2] Often normal at birth; slows later [16] Can be small or normal [15]
Speech Very few words; uses signs/AAC [17] Almost always non-verbal [16] Severe delay; speech is a struggle [14]
Gait Wide-based or “clumsy” [18] Jerky or “stiff” movements [16] Coordination issues [14][15]

Reading Your Genetic Report

When you receive your child’s genetic report, look for these key pieces of information (using illustrative examples) to share with your care team:

  1. Variant Type: Was it a nonsense or frameshift mutation (where the protein is cut short) or a missense mutation (where one “letter” is swapped for another)? [19][20]
  2. Location: The report will use codes like c.787C>T (the DNA change) and p.Arg263* (the protein change) to pinpoint exactly where the error is [19][21].
  3. Zygosity: It should say heterozygous, meaning only one of the two copies of the gene is affected [2][6].
  4. Classification: Look for the words Pathogenic or Likely Pathogenic, which mean the laboratory is confident this change causes the syndrome [7][22].

Common questions in this guide

What causes DYRK1A syndrome?
DYRK1A syndrome occurs when one copy of the DYRK1A gene on chromosome 21 is missing or does not work properly. This reduces the amount of DYRK1A protein available for brain development and growth, a mechanism called haploinsufficiency.
Does a child inherit DYRK1A syndrome from a parent?
In most children, the disease-causing change is new, meaning it arose in the egg, sperm, or early embryo and was not found in either parent’s blood. If neither parent carries the variant, the chance of recurrence is generally less than 1%, although rare germline mosaicism means the risk is not zero; if a parent carries the variant, the chance is 50%.
Which genetic tests can confirm DYRK1A syndrome?
Whole-exome or whole-genome sequencing can find small changes in the DYRK1A gene, while chromosomal microarray can detect larger deletions involving the gene. If a result is uncertain, DNA-methylation episignature testing may provide additional evidence, although it is not available everywhere.
What does a variant of uncertain significance in DYRK1A mean?
A variant of uncertain significance means the laboratory does not yet know whether the genetic change causes the condition. An episignature test may help clarify its importance in some cases, but a VUS alone should not be used to change treatment or make reproductive decisions.
How do I read my child’s DYRK1A genetic report?
Look for the variant type, such as a nonsense, frameshift, missense, or deletion change, along with the DNA and protein codes beginning with “c.” and “p.” The report should also state whether the change is heterozygous and classify it as pathogenic, likely pathogenic, or uncertain.
Why is DYRK1A syndrome compared with Angelman syndrome?
The conditions can share small head size, speech impairment, and gait or coordination differences, so appearance alone cannot reliably distinguish them. DYRK1A syndrome involves the DYRK1A gene on chromosome 21, while Angelman syndrome usually involves UBE3A and loss of maternal imprinting on chromosome 15; molecular testing can tell them apart.

Get notified when new evidence is published on Neurodevelopmental disorder with microcephaly, impaired language, and gait abnormalities.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID.

    van Bon BW, Coe BP, Bernier R, et al.

    Molecular psychiatry 2016; (21(1)):126-32 doi:10.1038/mp.2015.5.

    PMID: 25707398
  2. 2

    DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.

    Ji J, Lee H, Argiropoulos B, et al.

    European journal of human genetics : EJHG 2015; (23(11)):1473-81 doi:10.1038/ejhg.2015.71.

    PMID: 25944381
  3. 3

    Dyrk1a Mutations Cause Undergrowth of Cortical Pyramidal Neurons via Dysregulated Growth Factor Signaling.

    Levy JA, LaFlamme CW, Tsaprailis G, et al.

    Biological psychiatry 2021; (90(5)):295-306 doi:10.1016/j.biopsych.2021.01.012.

    PMID: 33840455
  4. 4

    Two remarkable cases of haploinsufficiency found in the DYRK1A gene.

    Taşdelen E, Tekbaş UC, Baş H, Sezer A

    Acta neurologica Belgica 2025; (125(3)):839-843 doi:10.1007/s13760-024-02685-9.

    PMID: 39572511
  5. 5

    DYRK1A roles in human neural progenitors.

    Courraud J, Quartier A, Drouot N, et al.

    Frontiers in neuroscience 2025; (19()):1533253 doi:10.3389/fnins.2025.1533253.

    PMID: 40182141
  6. 6

    DYRK1A pathogenic variants in two patients with syndromic intellectual disability and a review of the literature.

    Meissner LE, Macnamara EF, D'Souza P, et al.

    Molecular genetics & genomic medicine 2020; (8(12)):e1544 doi:10.1002/mgg3.1544.

    PMID: 33159716
  7. 7

    Case report: A novel de novo deletion mutation of DYRK1A is associated with intellectual developmental disorder, autosomal dominant 7.

    Zhou C, Zhu H, Xiang Q, et al.

    Frontiers in neuroscience 2023; (17()):1174925 doi:10.3389/fnins.2023.1174925.

    PMID: 37274198
  8. 8

    Familial recurrences of FOXG1-related disorder: Evidence for mosaicism.

    McMahon KQ, Papandreou A, Ma M, et al.

    American journal of medical genetics. Part A 2015; (167A(12)):3096-102 doi:10.1002/ajmg.a.37353.

    PMID: 26364767
  9. 9

    Identification of two novel and one rare mutation in DYRK1A and prenatal diagnoses in three Chinese families with intellectual Disability-7.

    Huang C, Luo H, Zeng B, et al.

    Frontiers in genetics 2023; (14()):1290949 doi:10.3389/fgene.2023.1290949.

    PMID: 38179410
  10. 10

    DYRK1A mutations in two unrelated patients.

    Ruaud L, Mignot C, Guët A, et al.

    European journal of medical genetics 2015; (58(3)):168-74.

    PMID: 25641759
  11. 11

    Copy-number variants in clinical genome sequencing: deployment and interpretation for rare and undiagnosed disease.

    Gross AM, Ajay SS, Rajan V, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(5)):1121-1130 doi:10.1038/s41436-018-0295-y.

    PMID: 30293986
  12. 12

    Episignature leads to diagnosis and reclassification of DYRK1A variant in a child with syndromic neurodevelopmental disorder: a case report.

    Al-Younis I, Basque L, Crapoulet N, et al.

    Frontiers in genetics 2026; (17()):1813300 doi:10.3389/fgene.2026.1813300.

    PMID: 42256340
  13. 13

    Angelman Syndrome.

    Margolis SS, Sell GL, Zbinden MA, Bird LM

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2015; (12(3)):641-50 doi:10.1007/s13311-015-0361-y.

    PMID: 26040994
  14. 14

    Detailed Clinical and Psychological Phenotype of the X-linked HNRNPH2-Related Neurodevelopmental Disorder.

    Bain JM, Thornburg O, Pan C, et al.

    Neurology. Genetics 2021; (7(1)):e551 doi:10.1212/NXG.0000000000000551.

    PMID: 33728377
  15. 15

    Heterozygous loss-of-function variants in DOCK4 cause neurodevelopmental delay and microcephaly.

    Herbst C, Bothe V, Wegler M, et al.

    Human genetics 2024; (143(3)):455-469 doi:10.1007/s00439-024-02655-4.

    PMID: 38526744
  16. 16

    Angelman syndrome in Hong Kong Chinese: A 20 years' experience.

    Luk HM, Lo IF

    European journal of medical genetics 2016; (59(6-7)):315-9.

    PMID: 27174604
  17. 17

    Social motivation a relative strength in DYRK1A syndrome on a background of significant speech and language impairments.

    Morison LD, Braden RO, Amor DJ, et al.

    European journal of human genetics : EJHG 2022; (30(7)):800-811 doi:10.1038/s41431-022-01079-w.

    PMID: 35437318
  18. 18

    Clinical and molecular overlap between nucleotide excision repair (NER) disorders and DYRK1A haploinsufficiency syndrome.

    Le May N, Courraud J, Boujelbène I, et al.

    Frontiers in neuroscience 2025; (19()):1554093 doi:10.3389/fnins.2025.1554093.

    PMID: 40206408
  19. 19

    Case report of novel DYRK1A mutations in 2 individuals with syndromic intellectual disability and a review of the literature.

    Luco SM, Pohl D, Sell E, et al.

    BMC medical genetics 2016; (17()):15 doi:10.1186/s12881-016-0276-4.

    PMID: 26922654
  20. 20

    Functional characterization of DYRK1A missense variants associated with a syndromic form of intellectual deficiency and autism.

    Widowati EW, Ernst S, Hausmann R, et al.

    Biology open 2018; (7(4)) doi:10.1242/bio.032862.

    PMID: 29700199
  21. 21

    A De Novo Mutation in DYRK1A Causes Syndromic Intellectual Disability: A Chinese Case Report.

    Qiao F, Shao B, Wang C, et al.

    Frontiers in genetics 2019; (10()):1194 doi:10.3389/fgene.2019.01194.

    PMID: 31803247
  22. 22

    DYRK1A syndrome presenting with a familial exudative vitreoretinopathy (FEVR)-like retinovascular phenotype.

    Lin S, Hay E, Thompson DA, et al.

    Ophthalmic genetics 2025; (46(4)):389-393 doi:10.1080/13816810.2025.2503388.

    PMID: 40405340

This page is for informational purposes only and does not constitute medical advice. A medical geneticist or genetic counselor should interpret your child’s report and discuss family-specific recurrence risk.